Emerging Market for Clinical Trials in Poland - Cost Advantages of Nearly 30% as Compared to the USGBI Research
December 31, 2011
103 Pages - SKU: XGBR6744082
Additional InformationGBI Research, the leading business intelligence provider, has released its latest report, “Emerging Market for Clinical Trials in Poland - Cost Advantages of Nearly 30% as Compared to the US” which provides key data, information and analysis of the major trends and issues affecting the clinical trial market in Poland. The report provides a comprehensive insight of the reasons for outsourcing clinical trials to Poland and the key services provided by the Clinical Research Organizations (CROs) of Poland. The report provides a detailed analysis of the Polish market in terms of its size, and major service offerings of the CROs in Poland. The report also discusses the factors that are driving the clinical trial market in Poland. The report delves into the key documents required by the investigator and the sponsor before, during and after the conduct of clinical trials. The report also provides key alliances in the CRO market. Furthermore, the report looks into the major challenges that can restrict the growth of the clinical trials market in Poland.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
Rising Costs of Drug Development and a Decrease in R&D Output have Resulted in the Outsourcing of Clinical Trials to Poland
Clinical Trials in Poland, Global, BLA and NME Approvals vs R&D Spending, ($bn), 1995-2010
Source: GBI Research, FDA, PhRMA.org
BLA: Biologic License Application; NME: New Molecule Entry; R&D: Research and Development
GBI Research suggests that over the years pharmaceutical R&D expenditure has been increasing relative to the number of drug approvals. The decreasing number of New Molecular Entities (NME) approvals against ever increasing R&D expenditure has made it difficult for pharmaceutical companies to extract a better Return on Investment (ROI) from their drugs as the cost of developing a single drug has increased exponentially.
Poland holds a strategic advantage in the cost of conducting clinical trials and is much cheaper than in the US. The cost per trial in Poland is nearly 30% less than the cost in the US. The costs of a clinical trial conducted in Poland are relatively low due to a high rate of patient recruitment and excellent quality of data, leading to a reduced number of rejected clinical trials recordings and time-efficient proceedings.
Poland is an Attractive Market for Contract Research Organizations due to Rapid Patient Recruitment and Good Quality Clinical Trial Data
Patient recruitment for clinical trials in western countries is difficult as people have either access to good medical care from government hospitals or they have medical insurance by which they can afford treatment even in private hospitals. However in Poland, access to the national health system is limited and medications is expensive, and hence, with the offer of better medical care, free drugs and diagnostic procedures, patient recruitment in clinical trials is very high. In fact, the comparison of patient recruitment for clinical trials from 2005 to 2009 in Eastern European countries showed that Poland came at the top. The increased benefits for patients participating in clinical trials in turn leads to highly motivated investigators, as they can see the benefits in the work they do more than their colleagues in Western countries. The comparison of the number of US Food and Drug Administration (FDA) audit site inspections carried out between 1997 and 2008 in various countries worldwide showed that Poland has a high standard of clinical trial procedures and provides good quality clinical trial data.
Clinical Trial Market in Poland is Expected to Grow at a Rate of 4% from 2010 to 2015
Clinical Trials in Poland, Poland, Clinical Trial Market, ($m), 2006 - 2015
Source: GBI Research, Primary Research
In 2010, the Polish clinical trial market was worth $265.7m, growing at a compound annual growth rate (CAGR) of 5% from 2006. GBI Research predicts it will grow at 4% to reach $323.3m by 2015. Due to its patient population, speed of patient recruitment, and good quality clinical data, Poland is attracting major pharmaceutical companies to conduct clinical trials in the country. Legislative drawbacks regarding clinical trials and the long trial registration process are the current problems faced by the multi-national companies (MNC’s). However, if these problems are resolved the market may grow at an exorbitant rate in the future.
More Clinical Trial reports by GBI Research
Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth by GBI Research
Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive GrowthSummaryThe leading ...
Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail by GBI Research
Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials FailSummaryLeading ...
Mobile Health (mHealth) - Enhancing Healthcare and Improving Clinical Outcomes by GBI Research
Mobile Health (mHealth) - Enhancing Healthcare and Improving Clinical OutcomesSummaryGBI Research, the leading business intelligence provider, has released its latest research report: “Mobile Health (mHealth) ...
Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share by GBI ResearchSee all reports like this >>
Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market ShareSummaryGBI Research, the leading business intelligence provider, has released its ...
More United States Clinical Trial reports
TreatmentTrends®: Advanced/Metastatic Breast Cancer (US) 2012 by Decision Resources
This report series examines the current trends in the management of Advanced / Metastatic Breast Cancer from the perspective of medical oncologists. TreatmentTrends® are syndicated ...
ChartTrends®: Lupus (US) 2012 by Decision Resources
This report is an annual publication that provides comprehensive insight into the management of systemic lupus erythematosus (SLE) patients being treated with immunosuppressants, corticosteroids, anti-malarials, ...
ChartTrends®: Bone and Mineral Metabolism in CKD-ND (US) 2012 by Decision Resources
ChartTrends®: Bone and Mineral Metabolism in CKD is a syndicated report that captures patient level data from 1000+ unique late stage (Stage 3 / Stage ...
Early Toxicology: Markets and Approaches by Kalorama InformationSee all reports like this >>
Early toxicology testing is emerging as one of the mostsignificant areas of drug discovery. Toxicity is no longer something that can be left to the ...
More United States reports
The 2013-2018 Outlook for Relish in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for relish across the states and cities of the United States. Latent demand (in millions of U.S. ...
The 2013-2018 Outlook for Indian Breads in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for Indian breads across the states and cities of the United States. Latent demand (in millions of ...
D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by Dun & Bradstreet Inc.See all reports like this >>
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
We can help you find what you need. Call us or write us:
Need help in your search?
Clinical Trial Reports
- Inflammatory Pain Global Clinical Trials Review, H1, 2013
- Cancer Pain Global Clinical Trials Review, H1, 2013
- Ascites Global Clinical Trials Review, H1, 2013
- Perspective: StudyOptimizer — Empowering Clinical Trial Enrollment Collaboration at Big Pharma
- Radiculopathy Global Clinical Trials Review, H1, 2013